Triple-negative breast cancer: promising prognostic biomarkers currently in development-Reference-Cited by-同舟云学术

Triple-negative breast cancer: promising prognostic biomarkers currently in development

Published:2021-02-01 Issue:2 Volume:21 Page:135-148
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Sukumar Jasmine¹,Gast Kelly¹,Quiroga Dionisia¹,Lustberg Maryam¹,Williams Nicole¹

Affiliation:

1. Division of Medical Oncology, The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, OH, USA

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1840984

Reference124 articles.

1. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

2. Triple-negative breast cancer: epidemiological considerations and recommendations

3. Triple negative breast cancer: A thorough review of biomarkers

4. Clinical implications of molecular heterogeneity in triple negative breast cancer

5. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway;Expert Review of Anticancer Therapy;2024-09-10

2. Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer;Journal of Personalized Medicine;2024-09-05

3. Next-generation biomarkers for prognostic and potential therapeutic enhancement in Triple negative breast cancer;Critical Reviews in Oncology/Hematology;2024-09

4. Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-18

5. Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy;Bioengineering;2024-08-14